SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (5118)12/14/1997 9:07:00 PM
From: Robert K.  Read Replies (3) | Respond to of 17367
 
Regarding ANCA implications, I have stated before so here is a brief repeat IMO. It seems (on the surface) they are using bpi21 in cf to overcome infections and/or resistance. However in a small study 88%
of cf patients had anca to bpi. Since bpi is part of natuaral host defense to infection, then one might say that lack of host defense might be a contributing cause of infection. If lack of anca to bpi 21,then bpi21 might be even better


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News